Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases [EXTENSION OF 700027920]

Trial Profile

Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases [EXTENSION OF 700027920]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 04 May 2013 Planned number of patients changed from 58 to 60 as reported by European Clinical Trials Database.
    • 04 May 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2008-005182-66).
    • 05 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top